However, it should be considered that also in trials investigating cardiovascular outcomes with SGLT2 inhibitors [4–6], these medications improved heart failure outcomes and cardiovascular mortality but not typical atherothrombotic endpoints such as myocardial infarctions or strokes. The gene discussed is SLC5A2; the disease is heart failure.